Comparative Pharmacology
Head-to-head clinical analysis: DASATINIB versus QLOSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASATINIB versus QLOSI.
DASATINIB vs QLOSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It inhibits BCR-ABL autophosphorylation and downstream signaling, leading to apoptosis in Philadelphia chromosome-positive (Ph+) leukemia cells.
QLOSI is a monoclonal antibody that binds to and inhibits the activity of interleukin-5 (IL-5), thereby reducing eosinophil production and survival.
140 mg orally once daily; reduce to 100 mg once daily if no cytogenetic response after 3 months or 140 mg once daily with dose escalation to 200 mg once daily as tolerated.
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours. This short half-life supports twice-daily dosing, but active metabolite (N-desmethyl dasatinib) has a similar half-life and contributes to PD activity.
Clinical Note
moderateDasatinib + Deslanoside
"Dasatinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDasatinib + Acetyldigitoxin
"Dasatinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateDasatinib + Ouabain
"Dasatinib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderateDasatinib + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Dasatinib."
Terminal elimination half-life is approximately 9 hours; clinical context: allows twice-daily dosing in patients with normal renal function.
Approximately 85% of the dose is eliminated via feces (mainly as metabolites), and about 4% via urine (parent drug and metabolites). Less than 1% is excreted unchanged in urine.
Primarily renal excretion of unchanged drug (approximately 85%), with the remainder eliminated via biliary/fecal routes (15%).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor